EX-99.2 3 a2019q4exhibit992.htm EXHIBIT 99.2 Exhibit
Exhibit 99.2


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FOURTH QUARTER
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 $ 10,774
 
       10,629
 
             1.4
%
             1.4
 
—
 
 
 
 
 
 
 
 
 
 
Europe
         4,663
 
         4,730
 
(1.4)
 
             1.0
 
            (2.4)
Western Hemisphere excluding U.S.
         1,495
 
         1,456
 
             2.6
 
             9.3
 
            (6.7)
Asia-Pacific, Africa
         3,815
 
         3,579
 
             6.6
 
             5.8
 
             0.8
International
         9,973
 
         9,765
 
             2.1
 
             4.0
 
            (1.9)
 
 
 
  
 
  
 
  
 
  
Worldwide
 $ 20,747
 
       20,394
 
             1.7
%
             2.6
 
            (0.9)
 
 
 
  
 
  
 
  
 
  
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.








Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
TWELVE MONTHS
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 $ 42,097
 
       41,884
 
             0.5
%
             0.5
 
—
 
 
 
 
 
 
 
 
 
 
Europe
       18,466
 
       18,753
 
            (1.5)
 
             3.8
 
            (5.3)
Western Hemisphere excluding U.S.
         5,941
 
         6,113
 
            (2.8)
 
             5.7
 
            (8.5)
Asia-Pacific, Africa
       15,555
 
       14,831
 
             4.9
 
             6.9
 
            (2.0)
International
       39,962
 
       39,697
 
             0.7
 
             5.3
 
            (4.6)
 
 
 
  
 
  
 
  
 
  
Worldwide
 $ 82,059
 
       81,581
 
             0.6
%
             2.8
 
            (2.2)
 
 
 
  
 
  
 
  
 
  
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
 




Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FOURTH QUARTER
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
 $ 1,470
 
         1,479
 
            (0.6)
%
            (0.6)
 
—
    International
         2,097
 
         2,057
 
             2.0
 
             4.0
 
            (2.0)
 
         3,567
   
         3,536
 
             0.9
 
             2.1
 
            (1.2)
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
         6,169
 
         5,936
 
             3.9
 
             3.9
 
—
    International
         4,379
 
         4,254
 
             2.9
 
             5.1
 
            (2.2)
 
       10,548
   
       10,190
 
             3.5
 
             4.4
 
            (0.9)
 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
    U.S.
         3,135
   
         3,214
 
            (2.4)
 
            (2.4)
 
—
    International
         3,497
 
         3,454
 
             1.3
 
             2.7
 
            (1.4)
 
         6,632
   
         6,668
 
            (0.5)
 
             0.2
 
            (0.7)
 
 
 
 
 
 
 
 
 
 
U.S.
       10,774
 
       10,629
 
             1.4
 
             1.4
 
—
International
         9,973
 
         9,765
 
             2.1
 
             4.0
 
            (1.9)
Worldwide
 $ 20,747
 
       20,394
 
             1.7
%
             2.6
 
            (0.9)
 
   
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
TWELVE MONTHS
 
 
 
 
 
Percent Change
 
2019
 
2018
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer
 
 
 
 
 
 
 
 
 
    U.S.
 $ 5,839
 
         5,761
 
             1.4
%
             1.4
 
—
    International
         8,059
 
         8,092
 
            (0.4)
 
             4.2
 
            (4.6)
 
       13,898
   
       13,853
 
             0.3
 
             3.0
 
            (2.7)
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
       23,874
 
       23,286
 
             2.5
 
             2.5
 
—
    International
       18,324
 
       17,448
 
             5.0
 
           10.1
 
            (5.1)
 
       42,198
   
       40,734
 
             3.6
 
             5.8
 
            (2.2)
 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
    U.S.
       12,384
   
       12,837
 
            (3.5)
 
            (3.5)
 
—
    International
       13,579
 
       14,157
 
            (4.1)
 
            (0.1)
 
            (4.0)
 
       25,963
   
       26,994
 
            (3.8)
 
            (1.7)
 
            (2.1)
 
 
 
 
 
 
 
 
 
 
U.S.
       42,097
 
       41,884
 
             0.5
 
             0.5
 
—
International
       39,962
 
       39,697
 
             0.7
 
             5.3
 
            (4.6)
Worldwide
 $ 82,059
 
       81,581
 
             0.6
%
             2.8
 
            (2.2)
 
   
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
 



Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
FOURTH QUARTER
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
Percent
 
 
 
Percent
 
 
 
Percent
 
Increase
 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 $ 20,747
 
100.0
 
 $ 20,394
 
100.0
 
1.7
Cost of products sold
      7,134
 
34.4
 
      6,961
 
34.1
 
2.5
Gross Profit
    13,613
 
65.6
 
    13,433
 
65.9
 
1.3
Selling, marketing and administrative expenses
      6,039
 
29.1
 
      5,991
 
29.4
 
0.8
Research and development expense
      3,232
 
15.6
 
      3,224
 
15.8
 
0.2
Interest (income) expense, net
             4
 
0.0
 
           54
 
0.3
 
 
Other (income) expense, net
           16
 
0.1
 
         978
 
4.8
 
 
Restructuring
         104
 
0.5
 
           64
 
0.3
 
 
Earnings before provision for taxes on income
      4,218
 
20.3
 
      3,122
 
15.3
 
35.1
Provision for taxes on income
         208
 
1.0
 
           80
 
0.4
 
160.0
Net earnings
 $ 4,010
 
19.3
 
 $ 3,042
 
14.9
 
31.8
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 1.50
 
 
 
 $ 1.12
 
 
 
33.9
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,669.1
 
 
 
2,724.0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
4.9
%
 
 
2.6
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 5,628
 
27.1
 
 $ 6,046
 
29.6
 
(6.9)
Net earnings
 $ 5,027
 
24.2
 
 $ 5,372
 
26.3
 
(6.4)
Net earnings per share (Diluted)
 $ 1.88
 
 
 
 $ 1.97
 
 
 
(4.6)
Effective tax rate
10.7
%
 
 
11.1
%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
TWELVE MONTHS
 
 
 
 
 
 
 
 
 
 
 
2019
 
2018
 
Percent
 
 
 
Percent
 
 
 
Percent
 
Increase
 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)
Sales to customers
 $ 82,059
 
100.0
 
 $ 81,581
 
100.0
 
0.6
Cost of products sold
    27,556
 
33.6
 
    27,091
 
33.2
 
1.7
Gross Profit
    54,503
 
66.4
 
    54,490
 
66.8
 
0.0
Selling, marketing and administrative expenses
    22,178
 
27.0
 
    22,540
 
27.6
 
(1.6)
Research and development expense
    11,355
 
13.8
 
    10,775
 
13.2
 
5.4
In-process research and development
         890
 
1.1
 
      1,126
 
1.4
 
 
Interest (income) expense, net
         (39)
 
0.0
 
         394
 
0.5
 
 
Other (income) expense, net
      2,525
 
3.1
 
      1,405
 
1.7
 
 
Restructuring
         266
 
0.3
 
         251
 
0.3
 
 
Earnings before provision for taxes on income
    17,328
 
21.1
 
    17,999
 
22.1
 
(3.7)
Provision for taxes on income
      2,209
 
2.7
 
      2,702
 
3.3
 
(18.2)
Net earnings
 $ 15,119
 
18.4
 
 $ 15,297
 
18.8
 
(1.2)
 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 5.63
 
 
 
 $ 5.61
 
 
 
0.4
 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,684.3
 
 
 
2,728.7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
12.7
%
 
 
15.0
%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 28,225
 
34.4
 
 $ 26,698
 
32.7
 
5.7
Net earnings
 $ 23,310
 
28.4
 
 $ 22,315
 
27.4
 
4.5
Net earnings per share (Diluted)
 $ 8.68
 
 
 
 $ 8.18
 
 
 
6.1
Effective tax rate
17.4
%
 
 
16.4
%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
 
 
Fourth Quarter
 
% Incr. /
 
(Dollars in Millions Except Per Share Data)
 
2019
 
2018
 
(Decr.)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as reported
 
 $ 4,218

 
          3,122
 
            35.1

%
Litigation expense, net
 
              264

 
          1,288
 
 
 
Intangible asset amortization expense
 
           1,142

 
          1,073
 
 
 
Restructuring/Other (1)
 
              251

 
             227
 
 
 
Actelion acquisition related cost
 
                62

 
               43
 
 
 
Auris Health acquisition related cost
 
                16

 
—
 
 
 
AMO acquisition related cost
 
                12

 
               27
 
 
 
Unrealized loss/(gain) on securities
 
            (350)

 
             182
 
 
 
Tax legislation and related impacts
 
—

   
               72
   
 
 
Other
 
                13

 
               12
 
 
 
Earnings before provision for taxes on income - as adjusted
 
 $ 5,628

 
          6,046
 
(6.9
)
%
 
 
 
 
 
 
 
 
Net Earnings - as reported
 
 $ 4,010

 
          3,042
 
            31.8

%
Litigation expense, net
 
              251

   
          1,113
   
 
 
Intangible asset amortization expense
 
           1,008

 
             957
 
 
 
Restructuring/Other
 
              214

 
             190
 
 
 
Actelion acquisition related cost
 
                58

 
               39
 
 
 
Auris Health acquisition related cost
 
                12

 
—
 
 
 
AMO acquisition related cost
 
                12

 
               21
 
 
 
Unrealized loss/(gain) on securities
 
(277
)
 
             143
 
 
 
Tax legislation and related impacts (2)
 
            (184)

   
           (137)
   
 
 
Other
 
              (77)

 
                 4
 
 
 
Net Earnings - as adjusted
 
 $ 5,027

 
          5,372
 
(6.4
)
%
 
 
 
 
 
 
 
 
Diluted Net Earnings per share - as reported
 
 $ 1.50

 
            1.12
 
            33.9

%
Litigation expense, net
 
             0.10

 
            0.41
 
 
 
Intangible asset amortization expense
 
             0.38

 
            0.35
 
 
 
Restructuring/Other
 
             0.08

 
            0.07
 
 
 
Actelion acquisition related cost
 
             0.02

 
            0.01
 
 
 
Auris Health acquisition related cost
 
—

 
—
 
 
 
AMO acquisition related cost
 
—

 
            0.01
 
 
 
Unrealized loss/(gain) on securities
 
           (0.10)

 
            0.05
 
 
 
Tax legislation and related impacts
 
           (0.07)

 
          (0.05)
 
 
 
Other
 
           (0.03)

 
—
 
 
 
Diluted Net Earnings per share - as adjusted
 
 $ 1.88

 
            1.97
 
(4.6
)
%
 
 
 
 
 
 
 
 
Impact of currency at 2018 foreign currency exchange rates
 
             0.03

 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted at 2018 foreign currency exchange rates
 
 $ 1.91

 
            1.97
 
            (3.0)

 %
 
 
 
 
 
 
 
 
(1) Includes $70M recorded in cost of products sold and $77M recorded in other (income) expense for the fourth quarter 2019. Includes $32M recorded in cost of products sold and $131M recorded in other (income) expense for the fourth quarter 2018.
    
 
 
 
 
 
 
(2) Includes foreign currency translation
 
 
 
 
 
 
 





Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
 
 
Twelve Months
 
% Incr. /
 
(Dollars in Millions Except Per Share Data)
 
2019
 
2018
 
(Decr.)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income - as reported
 
 $ 17,328
 
       17,999
 
            (3.7)
%
Litigation expense, net
 
         5,096
 
         1,991
 
 
 
Intangible asset amortization expense
 
         4,528
 
         4,357
 
 
 
In-process research and development
 
            890
 
         1,126
 
 
 
Restructuring/Other (1)
 
            611
 
            700
 
 
 
Actelion acquisition related cost
 
            185
 
            243
 
 
 
Auris Health acquisition related cost
 
              72
 
—
 
 
 
AMO acquisition related cost
 
              62
 
            109
 
 
 
Unrealized loss/(gain) on securities
 
           (567)
 
            179
 
 
 
Contingent liability reversal
 
—
 
           (184)
 
 
 
Tax legislation and related impacts
 
—
 
              72
 
 
 
Other
 
              20
 
            106
 
 
 
Earnings before provision for taxes on income - as adjusted
 
 $ 28,225
 
       26,698
 
             5.7
 %
 
 
 
 
 
 
 
 
Net Earnings - as reported
 
 $ 15,119
 
       15,297
 
            (1.2)
%
Litigation expense, net
 
         4,015
 
         1,722
 
 
 
Intangible asset amortization expense
 
         3,844
 
         3,888
 
 
 
In-process research and development
 
            703
 
            859
 
 
 
Restructuring/Other
 
            511
 
            585
 
 
 
Actelion acquisition related cost
 
            172
 
            232
 
 
 
Auris Health acquisition related cost
 
              56
 
—
 
 
 
AMO acquisition related cost
 
              52
 
              89
 
 
 
Unrealized loss/(gain) on securities
 
           (448)
 
            141
 
 
 
Contingent liability reversal
 
—
 
           (184)
 
 
 
Tax legislation and related impacts (2)
 
           (575)
 
           (390)
 
 
 
Other
 
           (139)
 
              76
 
 
 
Net Earnings - as adjusted
 
 $ 23,310
 
       22,315
 
             4.5
 %
 
 
 
 
 
 
 
 
Diluted Net Earnings per share - as reported
 
 $ 5.63
 
           5.61
 
             0.4
%
Litigation expense, net
 
           1.50
 
           0.63
 
 
 
Intangible asset amortization expense
 
           1.43
 
           1.42
 
 
 
In-process research and development
 
           0.26
 
           0.32
 
 
 
Restructuring/Other
 
           0.19
 
           0.21
 
 
 
Actelion acquisition related cost
 
           0.06
 
           0.09
 
 
 
Auris Health acquisition related cost
 
           0.02
 
—
 
 
 
AMO acquisition related cost
 
           0.02
 
           0.03
 
 
 
Unrealized loss/(gain) on securities
 
          (0.17)
 
           0.05
 
 
 
Contingent liability reversal
 
—
 
          (0.07)
 
 
 
Tax legislation and related impacts
 
          (0.21)
 
          (0.14)
 
 
 
Other
 
          (0.05)
 
           0.03
 
 
 
Diluted Net Earnings per share - as adjusted
 
 $ 8.68
 
           8.18
 
             6.1
 %
 
 
 
 
 
 
 
 
Impact of currency at 2018 foreign currency exchange rates
 
           0.22
 
 
 
 
 
Operational Diluted Net Earnings per share - as adjusted at 2018 foreign currency exchange rates
 
 $ 8.90
 
           8.18
 
             8.8
 %
 
 
 
 
 
 
 
 
(1) Includes $151M recorded in cost of products sold and $194M recorded in other (income) expense for twelve months YTD 2019. Includes $105M recorded in cost of products sold and $344M recorded in other (income) expense for twelve months YTD 2018.
 
 
 
 
 
 
 
(2) Includes foreign currency translation
 
 
 
 
 
 
 


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted Operational Sales Growth (A)
 FOURTH QUARTER 2019 ACTUAL vs. 2018 ACTUAL
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Segments
 
 
 
 
 
 Consumer
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 WW As Reported
 
0.9%
 
3.5%
 
(0.5)%
 
1.7%
 U.S.
 
(0.6)%
 
3.9%
 
(2.4)%
 
1.4%
 International
 
2.0%
 
2.9%
 
1.3%
 
2.1%
 
 
 
 
 
 
 
 
 
 WW Currency
 
(1.2)
 
(0.9)
 
(0.7)
 
(0.9)
 U.S.
 
—
 
—
 
—
 
—
 International
 
(2.0)
 
(2.2)
 
(1.4)
 
(1.9)
 
 
 
 
 
 
 
 
 
 WW Operational
 
2.1%
 
4.4%
 
0.2%
 
2.6%
 U.S.
 
(0.6)%
 
3.9%
 
(2.4)%
 
1.4%
 International
 
4.0%
 
5.1%
 
2.7%
 
4.0%
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
RoC
 
0.6
 
 
 
 
 
0.1
 U.S.
 
1.4
 
 
 
 
 
0.2
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Dr. Ci Labo - Japan
 
(1.7)
 
 
 
 
 
(0.3)
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(2.9)
 
 
 
 
 
(0.6)
 
 
 
 
 
 
 
 
 
Specialty Surgery
 
 
 
 
 
 
 
 
Advanced Sterilization Products
 
 
 
 
 
2.4
 
0.8
 U.S.
 
 
 
 
 
3.0
 
0.9
 International
 
 
 
 
 
2.0
 
0.7
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
Baby Center
 
0.3
 
 
 
 
 
0.1
 U.S.
 
0.8
 
 
 
 
 
0.1
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
0.0
 
0.1
 
0.1
 
0.1
 U.S.
 
0.0
 
0.1
 
0.0
 
0.1
 International
 
0.1
 
0.0
 
0.1
 
0.1
 
 
 
 
 
 
 
 
 
WW Adjusted Operational
 
1.4%
 
4.5%
 
2.7%
 
3.4%
 U.S.
 
1.6%
 
4.1%
 
0.6%
 
2.7%
 International
 
1.3%
 
5.1%
 
4.7%
 
4.1%
 
 
 
 
 
 
 
 
 
Note: Percentages are based on actual, non-rounded figures and may not sum
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.




Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted Operational Sales Growth (A)
 TWELVE MONTHS 2019 ACTUAL vs. 2018 ACTUAL
 
 Segments
 
 
 
 
 
 
 
 
 
 
 
 Consumer
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 WW As Reported
 
0.3%
 
3.6%
 
(3.8)%
 
0.6%
 U.S.
 
1.4%
 
2.5%
 
(3.5)%
 
0.5%
 International
 
(0.4)%
 
5.0%
 
(4.1)%
 
0.7%
 
 
 
 
 
 
 
 
 
 WW Currency
 
(2.7)
 
(2.2)
 
(2.1)
 
(2.2)
 U.S.
 
—
 
—
 
—
 
—
 International
 
(4.6)
 
(5.1)
 
(4.0)
 
(4.6)
 
 
 
 
 
 
 
 
 
 WW Operational
 
3.0%
 
5.8%
 
(1.7)%
 
2.8%
 U.S.
 
1.4%
 
2.5%
 
(3.5)%
 
0.5%
 International
 
4.2%
 
10.1%
 
(0.1)%
 
5.3%
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Nizoral
 
0.2
 
 
 
 
 
0.0
 U.S.
 
0.1
 
 
 
 
 
0.0
 International
 
0.3
 
 
 
 
 
0.1
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
Zarbees
 
(0.4)
 
 
 
 
 
(0.1)
 U.S.
 
(1.1)
 
 
 
 
 
(0.1)
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
LifeScan
 
 
 
 
 
3.8
 
1.3
 U.S.
 
 
 
 
 
2.9
 
0.9
 International
 
 
 
 
 
4.6
 
1.7
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
RoC
 
0.7
 
 
 
 
 
0.1
 U.S.
 
1.3
 
 
 
 
 
0.2
 International
 
0.2
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
Beauty
 
 
 
 
 
 
 
 
Dr. Ci Labo - Japan
 
(2.3)
 
 
 
 
 
(0.4)
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(3.9)
 
 
 
 
 
(0.8)
 
 
 
 
 
 
 
 
 
Specialty Surgery
 
 
 
 
 
 
 
 
Advanced Sterilization Products
 
 
 
 
 
1.6
 
0.6
 U.S.
 
 
 
 
 
2.2
 
0.7
 International
 
 
 
 
 
1.0
 
0.4
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
Baby Center
 
0.1
 
 
 
 
 
0.0
 U.S.
 
0.3
 
 
 
 
 
0.0
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
0.1
 
0.0
 
0.1
 
0.1
 U.S.
 
0.0
 
0.1
 
0.1
 
0.1
 International
 
0.1
 
0.0
 
0.1
 
0.1
 
 
 
 
 
 
 
 
 
WW Adjusted Operational
 
1.4%
 
5.8%
 
3.9%
 
4.5%
 U.S.
 
2.1%
 
2.7%
 
1.8%
 
2.3%
 International
 
1.0%
 
10.1%
 
5.7%
 
6.7%
 
 
 
 
 
 
 
 
 
Note: Percentages are based on actual, non-rounded figures and may not sum
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.






Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
85

 
116

 
(26.7
)%
(26.7
)%
—
 %
Intl
 
 
336

 
357

 
(5.9
)
(3.7
)
(2.2
)
WW
 
 
421

 
473

 
(11.0
)
(9.3
)
(1.7
)
 
 
 
 
 
 
 
 
 
 
BEAUTY
 
 
 
 
 
 
 
 
 
US
 
 
582

 
612

 
(4.9
)
(4.9
)
—

Intl
 
 
568

 
499

 
13.8

15.6

(1.8
)
WW
 
 
1,150

 
1,111

 
3.5

4.3

(0.8
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
159

 
165

 
(3.6
)
(3.6
)
—

Intl
 
 
233

 
234

 
0.2

2.2

(2.0
)
WW
 
 
393

 
399

 
(1.4
)
(0.2
)
(1.2
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
542

 
491

 
10.3

10.3

—

Intl
 
 
653

 
657

 
(0.6
)
0.8

(1.4
)
WW
 
 
1,195

 
1,148

 
4.1

4.9

(0.8
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
3

 
3

 
(11.8
)
(11.8
)
—

Intl
 
 
250

 
254

 
(1.5
)
3.1

(4.6
)
WW
 
 
253

 
257

 
(1.6
)
2.9

(4.5
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE / OTHER
 
 
 
 
 
 
 
 
 
US
 
 
98

 
92

 
7.5

7.5

—

Intl
 
 
57

 
56

 
(0.4
)
0.6

(1.0
)
WW
 
 
155

 
148

 
4.5

4.8

(0.3
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
US
 
 
1,470

 
1,479

 
(0.6
)
(0.6
)
—

Intl
 
 
2,097

 
2,057

 
2.0

4.0

(2.0
)
WW
 
$
3,567

 
3,536

 
0.9
 %
2.1
 %
(1.2
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
2,517

 
2,356

 
6.8
 %
6.8
 %
—
 %
Intl
 
 
1,005

 
986

 
1.9

4.3

(2.4
)
WW
 
 
3,522

 
3,342

 
5.4

6.1

(0.7
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
755

 
843
 
(10.4
)
(10.4
)
—

     US Exports (3)
 
 
68

 
90

 
(25.0
)
(25.0
)
—

     Intl
 
 
212

 
305

 
(30.4
)
(28.9
)
(1.5
)
     WW
 
 
1,035

 
1,238

 
(16.4
)
(16.0
)
(0.4
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
302

 
272

 
10.7

10.7

—

     Intl
 
 
213

 
210

 
1.4

3.7

(2.3
)
     WW
 
 
515

 
482

 
6.6

7.6

(1.0
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
1,194

 
1,009

 
18.4

18.4

—

     Intl
 
 
506

 
435

 
16.3

19.1

(2.8
)
     WW
 
 
1,700

 
1,444

 
17.7

18.6

(0.9
)
     TREMFYA
 
 
 
 
 
 
 
 
 
     US
 
 
199

 
142

 
39.7

39.7

—

     Intl
 
 
71

 
33

 
*

*

*

     WW
 
 
270

 
175

 
53.9

55.1

(1.2
)
     OTHER IMMUNOLOGY (4)
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
2

 
3

 
(22.4
)
(24.0
)
1.6

     WW
 
 
2

 
3

 
(22.4
)
(24.0
)
1.6

 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
435

 
372

 
17.1

17.1

—

Intl
 
 
430

 
430

 
0.2

3.0

(2.8
)
WW
 
 
866

 
802

 
8.0

9.6

(1.6
)
     EDURANT / rilpivirine
 
 
 
 
 
 
 
 
 
     US
 
 
14

 
16

 
(12.3
)
(12.3
)
—

     Intl
 
 
209

 
177

 
17.7

20.9

(3.2
)
     WW
 
 
222

 
193

 
15.2

18.2

(3.0
)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
 
 
 
 
 
 
     US
 
 
390

 
322

 
21.0

21.0

—

     Intl
 
 
155

 
173

 
(10.7
)
(7.8
)
(2.9
)
     WW
 
 
544

 
495

 
9.9

10.9

(1.0
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
32

 
34

 
(5.8
)
(5.8
)
—

     Intl
 
 
67

 
80

 
(15.4
)
(13.3
)
(2.1
)
     WW
 
 
99

 
114

 
(12.5
)
(11.0
)
(1.5
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
747

 
660

 
13.2
 %
13.2
 %
—
 %
Intl
 
 
819

 
840

 
(2.5
)
(1.2
)
(1.3
)
WW
 
 
1,566

 
1,500

 
4.4

5.2

(0.8
)
     CONCERTA / methylphenidate
 
 
 
 
 
 
 
 
 
     US
 
 
37

 
38

 
(4.4
)
(4.4
)
—

     Intl
 
 
115

 
112

 
2.4

3.0

(0.6
)
     WW
 
 
152

 
150

 
0.7

1.1

(0.4
)
     INVEGA SUSTENNA / XEPLION / INVEGA
 
 
 
 
 
     TRINZA / TREVICTA
 
 
 
 
 
 
 
 
 
     US
 
 
564

 
485

 
16.2

16.2

—

     Intl
 
 
308

 
278

 
10.7

13.2

(2.5
)
     WW
 
 
871

 
763

 
14.2

15.1

(0.9
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
77

 
77

 
0.3

0.3

—

     Intl
 
 
82

 
101

 
(18.9
)
(17.0
)
(1.9
)
     WW
 
 
160

 
178

 
(10.6
)
(9.5
)
(1.1
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
70

 
60

 
16.7

16.7

—

     Intl
 
 
314

 
349

 
(9.9
)
(9.3
)
(0.6
)
     WW
 
 
383

 
409

 
(6.1
)
(5.5
)
(0.6
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
1,153

 
1,063

 
8.5

8.5

—

Intl
 
 
1,563

 
1,426

 
9.6

12.2

(2.6
)
WW
 
 
2,716

 
2,489

 
9.1

10.6

(1.5
)
     DARZALEX
 
 
 
 
 
 
 
 
 
     US
 
 
444

 
323

 
37.8

37.8

—

     Intl
 
 
385

 
261

 
47.5

52.8

(5.3
)
     WW
 
 
830

 
584

 
42.1

44.5

(2.4
)
     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
392

 
318

 
22.8

22.8

—

     Intl
 
 
483

 
385

 
25.9

29.7

(3.8
)
     WW
 
 
875

 
703

 
24.5

26.6

(2.1
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
115

 
252

 
(54.6
)
(55.2
)
0.6

     WW
 
 
115

 
252

 
(54.6
)
(55.2
)
0.6

     ZYTIGA / abiraterone acetate
 
 
 
 
 
 
 
 
 
     US
 
 
194

 
351

 
(44.8
)
(44.8
)
—

     Intl
 
 
483

 
435

 
11.2

12.9

(1.7
)
     WW
 
 
677

 
786

 
(13.8
)
(12.9
)
(0.9
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
122

 
71

 
75.1

75.1

—

     Intl
 
 
97

 
93

 
3.0

5.9

(2.9
)
     WW
 
 
220

 
164

 
33.7

35.4

(1.7
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
US
 
$
388

 
436

 
(11.1
)%
(11.1
)%
—
 %
Intl
 
 
235

 
231

 
1.6

3.1

(1.5
)
WW
 
 
623

 
667

 
(6.7
)
(6.2
)
(0.5
)
     OPSUMIT
 
 
 
 
 
 
 
 
 
     US
 
 
185

 
189

 
(2.4
)
(2.4
)
—

     Intl
 
 
143

 
134

 
5.8

7.5

(1.7
)
     WW
 
 
326

 
323

 
1.0

1.7

(0.7
)
     TRACLEER / bosentan
 
 
 
 
 
 
 
 
 
     US
 
 
10

 
60

 
(83.3
)
(83.3
)
—

     Intl
 
 
46

 
64

 
(27.6
)
(28.8
)
1.2

     WW
 
 
56

 
124

 
(54.8
)
(55.4
)
0.6

     UPTRAVI
 
 
 
 
 
 
 
 
 
     US
 
 
178

 
165

 
7.4

7.4

—

     Intl
 
 
30

 
16

 
92.5

99.5

(7.0
)
     WW
 
 
208

 
181

 
14.8

15.4

(0.6
)
     OTHER
 
 
 
 
 
 
 
     US
 
 
16

 
22

 
(27.7
)
(27.7
)
—

     Intl
 
 
16

 
17

 
(5.9
)
(2.4
)
(3.5
)
     WW
 
 
32

 
39

 
(18.1
)
(16.5
)
(1.6
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER
 
 
 
 
 
 
US
 
$
930

 
1,049

 
(11.4
)%
(11.4
)%
—
 %
Intl
 
 
327

 
341

 
(4.4
)
(3.5
)
(0.9
)
WW
 
 
1,256

 
1,390

 
(9.7
)
(9.5
)
(0.2
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
609

 
608

 
0.4

0.4

—

     Intl
 
 
—

 
—

 
—

—

—

     WW
 
 
609

 
608

 
0.4

0.4

—

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
125

 
188

 
(33.8
)
(33.8
)
—

     Intl
 
 
52

 
40

 
33.7

36.0

(2.3
)
     WW
 
 
177

 
228

 
(22.2
)
(21.8
)
(0.4
)
     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
118

 
151

 
(21.6
)
(21.6
)
—

     Intl
 
 
65

 
70

 
(7.1
)
(7.0
)
(0.1
)
     WW
 
 
183

 
221

 
(17.0
)
(16.9
)
(0.1
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
78

 
102

 
(25.0
)
(25.0
)
—

     Intl
 
 
209

 
231

 
(10.0
)
(9.1
)
(0.9
)
     WW
 
 
286

 
333

 
(14.6
)
(14.0
)
(0.6
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
6,169

 
5,936

 
3.9

3.9

—

Intl
 
 
4,379

 
4,254

 
2.9

5.1

(2.2
)
WW
 
$
10,548

 
10,190

 
3.5
 %
4.4
 %
(0.9
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERVENTIONAL SOLUTIONS
 
 
 
 
 
 
 
 
 
US
 
 
377

 
336

 
12.2
 %
12.2
 %
—
 %
Intl
 
 
398

 
350

 
13.4

14.3

(0.9
)
WW
 
 
774

 
686

 
12.8

13.3

(0.5
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
 
 
 
 
 
US
 
 
1,369

 
1,358

 
0.9

0.9

—

Intl
 
 
904

 
904

 
(0.1
)
1.7

(1.8
)
WW
 
 
2,273

 
2,262

 
0.5

1.2

(0.7
)
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
     US
 
 
230

 
220

 
4.9

4.9

—

     Intl
 
 
147

 
145

 
1.2

3.0

(1.8
)
     WW
 
 
377

 
365

 
3.4

4.2

(0.8
)
 
 
 
 
 
 
 
 
 
 
     KNEES
 
 
 
 
     US
 
 
239

 
239

 
0.2

0.2

—

     Intl
 
 
156

 
153

 
1.5

3.2

(1.7
)
     WW
 
 
395

 
392

 
0.7

1.4

(0.7
)
 
 
 
 
 
 
 
 
 
 
     TRAUMA
 
 
 
 
 
 
 
 
 
     US
 
 
413

 
403

 
2.3

2.3

—

     Intl
 
 
273

 
271

 
0.8

2.6

(1.8
)
     WW
 
 
686

 
674

 
1.7

2.5

(0.8
)
 
 
 
 
 
 
 
 
 
 
     SPINE & OTHER
 
 
     US
 
 
488

 
496

 
(1.6
)
(1.6
)
—

     Intl
 
 
329

 
335

 
(2.1
)
(0.4
)
(1.7
)
     WW
 
 
817

 
831

 
(1.8
)
(1.1
)
(0.7
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 


Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FOURTH QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
SURGERY
 
 
 
 
 
 
US
 
$
961

 
1,094

 
(12.2
)%
(12.2
)%
—
 %
Intl
 
 
1,481

 
1,493

 
(0.8
)
1.2

(2.0
)
WW
 
 
2,442

 
2,587

 
(5.6
)
(4.4
)
(1.2
)
 
 
 
 
 
 
 
 
 
 
     ADVANCED
 
 
 
 
 
 
 
 
 
     US
 
 
428

 
441

 
(3.0
)
(3.0
)
—

     Intl
 
 
647

 
614

 
5.5

7.6

(2.1
)
     WW
 
 
1,076

 
1,055

 
2.0

3.2

(1.2
)
 
 
 
 
 
 
 
 
 
 
     GENERAL
 
 
 
 
 
 
 
 
 
     US
 
 
451

 
469

 
(3.9
)
(3.9
)
—

     Intl
 
 
720

 
712

 
1.2

3.3

(2.1
)
     WW
 
 
1,171

 
1,181

 
(0.8
)
0.4

(1.2
)
 
 
 
 
 
 
 
 
 
 
     SPECIALTY
 
 
 
 
 
 
 
 
 
     US
 
 
83

 
184

 
(55.3
)
(55.3
)
—

     Intl
 
 
114

 
167

 
(32.3
)
(30.7
)
(1.6
)
     WW
 
 
195

 
351

 
(44.4
)
(43.6
)
(0.8
)
 
 
 
 
 
 
 
 
 
 
VISION
 
 
 
 
US
 
 
428

 
426

 
0.3

0.3

—

Intl
 
 
713

 
707

 
1.0

1.2

(0.2
)
WW
 
 
1,141

 
1,133

 
0.7

0.9

(0.2
)
 
 
 
 
 
 
 
 
 
 
     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
311

 
289

 
7.7

7.7

—

     Intl
 
 
522

 
527

 
(0.8
)
(0.9
)
0.1

     WW
 
 
833

 
816

 
2.2

2.1

0.1

     SURGICAL
 
 
 
 
 
 
 
 
 
     US
 
 
117

 
137

 
(15.2
)
(15.2
)
—

     Intl
 
 
191

 
180

 
6.4

7.6

(1.2
)
     WW
 
 
309

 
317

 
(3.0
)
(2.3
)
(0.7
)
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
US
 
 
3,135

 
3,214

 
(2.4
)
(2.4
)
—

Intl
 
 
3,497

 
3,454

 
1.3

2.7

(1.4
)
WW
 
$
6,632

 
6,668

 
(0.5
)%
0.2
 %
(0.7
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

CONSUMER SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
362

 
422

 
(14.2
)%
(14.2
)%
—
 %
Intl
 
 
1,313

 
1,436

 
(8.6
)
(3.7
)
(4.9
)
WW
 
 
1,675

 
1,858

 
(9.9
)
(6.1
)
(3.8
)
 
 
 
 
 
 
 
 
 
 
BEAUTY
 
 
 
 
 
 
 
 
 
US
 
 
2,392

 
2,403

 
(0.4
)
(0.4
)
—

Intl
 
 
2,201

 
1,979

 
11.2

15.3

(4.1
)
WW
 
 
4,593

 
4,382

 
4.8

6.7

(1.9
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
621

 
637

 
(2.5
)
(2.5
)
—

Intl
 
 
906

 
918

 
(1.2
)
3.3

(4.5
)
WW
 
 
1,528

 
1,555

 
(1.7
)
0.9

(2.6
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
2,010

 
1,850

 
8.6

8.6

—

Intl
 
 
2,434

 
2,484

 
(2.0
)
2.2

(4.2
)
WW
 
 
4,444

 
4,334

 
2.5

4.9

(2.4
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
12

 
13

 
(5.5
)
(5.5
)
—

Intl
 
 
974

 
1,036

 
(6.0
)
1.1

(7.1
)
WW
 
 
986

 
1,049

 
(6.0
)
1.0

(7.0
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE / OTHER
 
 
 
 
 
 
 
 
 
US
 
 
441

 
436

 
1.2

1.2

—

Intl
 
 
230

 
239

 
(3.9
)
(0.7
)
(3.2
)
WW
 
 
671

 
675

 
(0.6
)
0.5

(1.1
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
US
 
 
5,839

 
5,761

 
1.4

1.4

—

Intl
 
 
8,059

 
8,092

 
(0.4
)
4.2

(4.6
)
WW
 
$
13,898

 
13,853

 
0.3
 %
3.0
 %
(2.7
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
9,641

 
9,073

 
6.3
 %
6.3
 %
—
 %
Intl
 
 
4,309

 
4,047

 
6.5

11.6

(5.1
)
WW
 
 
13,950

 
13,120

 
6.3

7.9

(1.6
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
3,079

 
3,664

 
(16.0
)
(16.0
)
—

     US Exports (3)
 
 
294

 
436

 
(32.7
)
(32.7
)
—

     Intl
 
 
1,007

 
1,226

 
(17.8
)
(13.7
)
(4.1
)
     WW
 
 
4,380

 
5,326

 
(17.8
)
(16.8
)
(1.0
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
1,159

 
1,051

 
10.2

10.2

—

     Intl
 
 
1,029

 
1,033

 
(0.4
)
4.4

(4.8
)
     WW
 
 
2,188

 
2,084

 
5.0

7.3

(2.3
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
4,346

 
3,469

 
25.3

25.3

—

     Intl
 
 
2,015

 
1,687

 
19.4

25.1

(5.7
)
     WW
 
 
6,361

 
5,156

 
23.4

25.2

(1.8
)
     TREMFYA
 
 
 
 
 
 
 
 
 
     US
 
 
764

 
453

 
68.5

68.5

—

     Intl
 
 
248

 
91

 
*

*

*

     WW
 
 
1,012

 
544

 
85.9

87.7

(1.8
)
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
10

 
10

 
4.5

4.7

(0.2
)
     WW
 
 
10

 
10

 
4.5

4.7

(0.2
)
 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
1,597

 
1,378

 
15.9

15.9

—

Intl
 
 
1,815

 
1,926

 
(5.7
)
(0.2
)
(5.5
)
WW
 
 
3,413

 
3,304

 
3.3

6.5

(3.2
)
     EDURANT / rilpivirine
 
 
 
 
 
 
 
 
 
     US
 
 
50

 
58

 
(13.7
)
(13.7
)
—

     Intl
 
 
812

 
758

 
7.1

12.7

(5.6
)
     WW
 
 
861

 
816

 
5.6

10.8

(5.2
)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
 
 
 
 
 
 
     US
 
 
1,422

 
1,169

 
21.6

21.6

—

     Intl
 
 
689

 
786

 
(12.3
)
(6.8
)
(5.5
)
     WW
 
 
2,110

 
1,955

 
8.0

10.2

(2.2
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
126

 
151

 
(16.5
)
(16.5
)
—

     Intl
 
 
315

 
382

 
(17.6
)
(12.3
)
(5.3
)
     WW
 
 
441

 
533

 
(17.3
)
(13.5
)
(3.8
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
2,919

 
2,574

 
13.4
 %
13.4
 %
—
 %
Intl
 
 
3,409

 
3,503

 
(2.7
)
1.5

(4.2
)
WW
 
 
6,328

 
6,077

 
4.1

6.6

(2.5
)
     CONCERTA / methylphenidate
 
 
 
 
 
 
 
 
 
     US
 
 
233

 
229

 
1.7

1.7

—

     Intl
 
 
463

 
434

 
6.6

10.3

(3.7
)
     WW
 
 
696

 
663

 
4.9

7.3

(2.4
)
     INVEGA SUSTENNA / XEPLION / INVEGA
 
 
 
 
 
     TRINZA / TREVICTA
 
 
 
 
 
 
 
 
 
     US
 
 
2,107

 
1,791

 
17.6

17.6

—

     Intl
 
 
1,224

 
1,137

 
7.7

13.0

(5.3
)
     WW
 
 
3,330

 
2,928

 
13.7

15.8

(2.1
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
314

 
315

 
(0.3
)
(0.3
)
—

     Intl
 
 
374

 
422

 
(11.4
)
(6.5
)
(4.9
)
     WW
 
 
688

 
737

 
(6.7
)
(3.9
)
(2.8
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
266

 
239

 
11.4

11.4

—

     Intl
 
 
1,349

 
1,510

 
(10.7
)
(7.4
)
(3.3
)
     WW
 
 
1,614

 
1,749

 
(7.7
)
(4.9
)
(2.8
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
4,299

 
4,331

 
(0.7
)
(0.7
)
—

Intl
 
 
6,393

 
5,513

 
16.0

21.8

(5.8
)
WW
 
 
10,692

 
9,844

 
8.6

11.9

(3.3
)
     DARZALEX
 
 
 
 
 
 
 
 
 
     US
 
 
1,567

 
1,203

 
30.3

30.3

—

     Intl
 
 
1,430

 
822

 
73.9

84.1

(10.2
)
     WW
 
 
2,998

 
2,025

 
48.0

52.2

(4.2
)
     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
1,555

 
1,129

 
37.7

37.7

—

     Intl
 
 
1,856

 
1,486

 
24.9

32.1

(7.2
)
     WW
 
 
3,411

 
2,615

 
30.4

34.5

(4.1
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
751

 
1,116

 
(32.7
)
(30.1
)
(2.6
)
     WW
 
 
751

 
1,116

 
(32.7
)
(30.1
)
(2.6
)
     ZYTIGA / abiraterone acetate
 
 
 
 
 
 
 
 
 
     US
 
 
810

 
1,771

 
(54.3
)
(54.3
)
—

     Intl
 
 
1,985

 
1,727

 
15.0

19.8

(4.8
)
     WW
 
 
2,795

 
3,498

 
(20.1
)
(17.7
)
(2.4
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
367

 
228

 
61.0

61.0

—

     Intl
 
 
371

 
362

 
2.4

8.1

(5.7
)
     WW
 
 
739

 
590

 
25.0

28.6

(3.6
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
US
 
$
1,684

 
1,651

 
2.0
 %
2.0
 %
—
 %
Intl
 
 
939

 
922

 
1.9

6.3

(4.4
)
WW
 
 
2,623

 
2,573

 
1.9

3.5

(1.6
)
     OPSUMIT
 
 
 
 
 
 
 
 
 
     US
 
 
766

 
700

 
9.4

9.4

—

     Intl
 
 
562

 
515

 
9.0

14.1

(5.1
)
     WW
 
 
1,327

 
1,215

 
9.2

11.4

(2.2
)
     TRACLEER / bosentan
 
 
 
 
 
 
 
 
 
     US
 
 
131

 
268

 
(51.1
)
(51.1
)
—

     Intl
 
 
210

 
278

 
(24.3
)
(22.6
)
(1.7
)
     WW
 
 
341

 
546

 
(37.5
)
(36.6
)
(0.9
)
     UPTRAVI
 
 
 
 
 
 
 
 
 
     US
 
 
714

 
598

 
19.3

19.3

—

     Intl
 
 
105

 
65

 
62.4

70.7

(8.3
)
     WW
 
 
819

 
663

 
23.5

24.3

(0.8
)
     OTHER
 
 
 
 
 
 
 
     US
 
 
74

 
85

 
(13.7
)
(13.7
)
—

     Intl
 
 
62

 
64

 
(3.7
)
3.3

(7.0
)
     WW
 
 
135

 
149

 
(9.4
)
(6.4
)
(3.0
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER
 
 
 
 
 
 
US
 
$
3,734

 
4,279

 
(12.7
)%
(12.7
)%
—
 %
Intl
 
 
1,458

 
1,537

 
(5.2
)
(1.3
)
(3.9
)
WW
 
 
5,192

 
5,816

 
(10.7
)
(9.7
)
(1.0
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
2,313

 
2,477

 
(6.6
)
(6.6
)
—

     Intl
 
 
—

 
—

 
—

—

—

     WW
 
 
2,313

 
2,477

 
(6.6
)
(6.6
)
—

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
536

 
711

 
(24.6
)
(24.6
)
—

     Intl
 
 
199

 
170

 
17.3

22.1

(4.8
)
     WW
 
 
735

 
881

 
(16.5
)
(15.6
)
(0.9
)
     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
505

 
674

 
(25.1
)
(25.1
)
—

     Intl
 
 
285

 
314

 
(9.2
)
(6.5
)
(2.7
)
     WW
 
 
790

 
988

 
(20.0
)
(19.2
)
(0.8
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
380

 
417

 
(9.1
)
(9.1
)
—

     Intl
 
 
974

 
1,053

 
(7.6
)
(3.5
)
(4.1
)
     WW
 
 
1,353

 
1,470

 
(8.0
)
(5.1
)
(2.9
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
23,874

 
23,286

 
2.5

2.5

—

Intl
 
 
18,324

 
17,448

 
5.0

10.1

(5.1
)
WW
 
$
42,198

 
40,734

 
3.6
 %
5.8
 %
(2.2
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (4)
 
 
 
 
 
 
 
 
 
 
 
 
 
DIABETES CARE (4)
 
 
 
 
 
 
US
 
$
—

 
371

 
*%

*%

—
 %
Intl
 
 
—

 
638

 
*

*

*

WW
 
 
—

 
1,009

 
*

*

*

 
 
 
 
 
 
 
 
 
 
INTERVENTIONAL SOLUTIONS
 
 
 
 
 
 
 
 
 
US
 
 
1,443

 
1,283

 
12.5

12.5

—

Intl
 
 
1,554

 
1,363

 
14.0

17.8

(3.8
)
WW
 
 
2,997

 
2,646

 
13.3

15.2

(1.9
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
 
 
 
 
 
US
 
 
5,319

 
5,281

 
0.7

0.7

—

Intl
 
 
3,520

 
3,604

 
(2.3
)
1.9

(4.2
)
WW
 
 
8,839

 
8,885

 
(0.5
)
1.2

(1.7
)
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
     US
 
 
863

 
841

 
2.6

2.6

—

     Intl
 
 
575

 
577

 
(0.3
)
4.2

(4.5
)
     WW
 
 
1,438

 
1,418

 
1.4

3.3

(1.9
)
 
 
 
 
 
 
 
 
 
 
     KNEES
 
 
 
 
     US
 
 
889

 
911

 
(2.4
)
(2.4
)
—

     Intl
 
 
591

 
591

 
0.0

4.1

(4.1
)
     WW
 
 
1,480

 
1,502

 
(1.4
)
0.2

(1.6
)
 
 
 
 
 
 
 
 
 
 
     TRAUMA
 
 
 
 
 
 
 
 
 
     US
 
 
1,652

 
1,599

 
3.3

3.3

—

     Intl
 
 
1,068

 
1,100

 
(2.9
)
1.4

(4.3
)
     WW
 
 
2,720

 
2,699

 
0.8

2.5

(1.7
)
 
 
 
 
 
 
 
 
 
 
     SPINE & OTHER
 
 
     US
 
 
1,915

 
1,930

 
(0.8
)
(0.8
)
—

     Intl
 
 
1,286

 
1,336

 
(3.8
)
0.4

(4.2
)
     WW
 
 
3,201

 
3,266

 
(2.0
)
(0.3
)
(1.7
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 


Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
TWELVE MONTHS
 
 
 
 
 
 
 
% Change
 
 
 
2019
 
2018
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (4) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
SURGERY
 
 
 
 
 
 
US
 
$
3,828

 
4,125

 
(7.2
)%
(7.2
)%
—
 %
Intl
 
 
5,673

 
5,776

 
(1.8
)
2.7

(4.5
)
WW
 
 
9,501

 
9,901

 
(4.0
)
(1.4
)
(2.6
)
 
 
 
 
 
 
 
 
 
 
     ADVANCED
 
 
 
 
 
 
 
 
 
     US
 
 
1,637

 
1,657

 
(1.2
)
(1.2
)
—

     Intl
 
 
2,458

 
2,345

 
4.8

9.4

(4.6
)
     WW
 
 
4,095

 
4,002

 
2.3

5.0

(2.7
)
 
 
 
 
 
 
 
 
 
 
     GENERAL
 
 
 
 
 
 
 
 
 
     US
 
 
1,762

 
1,751

 
0.6

0.6

—

     Intl
 
 
2,718

 
2,806

 
(3.1
)
1.3

(4.4
)
     WW
 
 
4,480

 
4,557

 
(1.7
)
1.0

(2.7
)
 
 
 
 
 
 
 
 
 
 
     SPECIALTY
 
 
 
 
 
 
 
 
 
     US
 
 
430

 
717

 
(40.1
)
(40.1
)
—

     Intl
 
 
497

 
625

 
(20.5
)
(16.4
)
(4.1
)
     WW
 
 
926

 
1,342

 
(31.0
)
(29.0
)
(2.0
)
 
 
 
 
 
 
 
 
 
 
VISION
 
 
 
 
US
 
 
1,794

 
1,777

 
0.9

0.9

—

Intl
 
 
2,830

 
2,776

 
2.0

4.9

(2.9
)
WW
 
 
4,624

 
4,553

 
1.6

3.3

(1.7
)
 
 
 
 
 
 
 
 
 
 
     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
1,304

 
1,237

 
5.4

5.4

—

     Intl
 
 
2,088

 
2,065

 
1.1

4.0

(2.9
)
     WW
 
 
3,392

 
3,302

 
2.7

4.6

(1.9
)
     SURGICAL
 
 
 
 
 
 
 
 
 
     US
 
 
490

 
540

 
(9.4
)
(9.4
)
—

     Intl
 
 
742

 
711

 
4.4

7.3

(2.9
)
     WW
 
 
1,232

 
1,251

 
(1.6
)
0.1

(1.7
)
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
US
 
 
12,384

 
12,837

 
(3.5
)
(3.5
)
—

Intl
 
 
13,579

 
14,157

 
(4.1
)
(0.1
)
(4.0
)
WW
 
$
25,963

 
26,994

 
(3.8
)%
(1.7
)%
(2.1
)%
 
 
 
 
 
 
 
 
 
 
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
 
 
 
 
 
 
 
 
 
 
* Percentage greater than 100% or not meaningful
 
 
 
 
(1) Operational growth excludes the effect of translational currency
 
 
(2) Unaudited
 
 
 
 
 
 
 
 
 
(3) Reported as U.S. sales
 
 
 
 
 
 
 
 
 
(4) Reflects LifeScan divestiture October 2, 2018